New Claims

Pharmacia Animal Health announces Antirobe® (clindamycin hydrochloride)capsules, antibiotics for dogs and cats, has received new clearances fromthe U.S. Food and Drug Administration (FDA). The FDA approved a new dosagerange for the product, plus a 300 mg capsule dosage option, giving veterinariansmore choices in prescribing the antibiotic. Antirobe is approved for treatmentof skin infections (abscesses and wounds), including those caused by Staphylococcusaureus and Staphylococcus intermedius. Antirobe also is approved for dentalinfections and osteomyelitis. The new dosage range means that it's now labeledfor administration at 2.5 to 15.0 mg per pound of body weight every 12 hoursfor dogs with skin infections (wounds and abscesses), or dental infections,the company says. The dosage range for dogs with osteomyelitis is 5.0 to15.0 mg every 12 hours. Its label indicates that treatment may be continuedup to a maximum of 28 days. For cats with skin infections (wounds and abscesses)or dental infections, Antirobe can be given at 5.0 to 15.0 mg per poundof body weight every 24 hours. Treatment may be continued up to a maximumof 14 days if clinical judgment indicates. The new 300 mg capsule dosagealso is significant, the company says. The 300 mg capsules provide veterinarianswith the same Antirobe quality, safety and benefits in a more convenientdosage for larger dogs. Both 150 mg and 300 mg dosages now are availableas blister packs.

For fastest response call (800) 793-0596 or visit the Web site at